June 2, 2021 | Blogs
The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified locally and whether a broader scope of therapies will be eligible for the scheme to deem the market more attractive for submissions.
May 25, 2021 | Blogs
Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.
April 14, 2021 | Blogs
In this three-part series, CBPartners’ Digital Therapeutics & Health Technology Expertise Team interviews some of the leaders of the digital therapeutics (DTx) space to collect their thoughts on the current challenges and opportunities for DTx commercialization.
November 3, 2020 | Blogs
New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.
October 29, 2020 | Blogs
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.